USE OF MICROVESICLES (MVS) FOR PREPARING A MEDICAMENT HAVING ADJUVANT ACTIVITY ON ENDOTHELIAL CELL TRANSPLANTATION, PARTICULARLY IN THE TREATMENT OF DIABETES BY PANCREATIC ISLET TRANSPLANTATION, AND RELATED METHOD

• US 20100233216A1
• Filed: 10/15/2007
• Published: 09/16/2010
• Est. Priority Date: 10/15/2007
• Status: Abandoned Application

• Current Assignee: Fresenius Medical Care Deutschland GmbH (Fresenius SE & Co. KGaA)
• Original Assignee: Fresenius Medical Care Deutschland GmbH (Fresenius SE & Co. KGaA)
• Inventors: Deregibus, Maria Chiara Armilde, Cantaluppi, Vincenzo, Camussi, Giovanni
• Application Number:
  US12/734,160
• Publication Number:
  US 20100233216A1
• Time in Patent Office: Days
• US Class Current: 424/278.100
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• CPC Class Codes: A61K 35/39 Pancreas; Islets of Langerhans Langerhans cells of epidermis A61K35/36
• CPC Class Codes: A61K 35/44 Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection

Abstract

The invention relates to the use of microvesicles derived from cells of the endothelial cell lineage, preferably from endothelial progenitor cells, as an adjuvant agent in endothelial cell-pancreatic islet transplantation, particularly in the treatment of type I or type II diabetes by pancreatic islet transplantation. The adjuvant effect of the microvesicles consists in the improvement of survival and functionality of the transplanted islets. The adjuvant effect of the microvesicles is maintained even when the recipient is subjected to rapamycin-based immunosuppression.

Claims

1-15. -15. (canceled)

16. The use of microvesicles (MVs) derived from a cell of the endothelial cell lineage for preparing a medicament having adjuvant activity on the treatment of type I and II diabetes by pancreatic islet transplantation.

17. The use according to claim 16, wherein the cell of the endothelial cell lineage is an endothelial progenitor cell (EPC).

18. The use according to claim 16, wherein the medicament is suitable for administration by intravenous infusion.

19. The use according to claim 16, wherein the medicament is suitable for administering a microvesicle dose comprised between 0.1 and 10 micrograms/Kg recipient weight.

20. The use according to claim 16, wherein the pancreatic islet transplantation procedure includes at least one step in which the recipient is subjected to rapamycin-based immunosuppression before and/or during and/or after transplantation.

21. A method of endothelial cell transplantation, comprising administering microvesicles (MVs) derived from a cell of the endothelial cell lineage to the transplant recipient.

22. The method according to claim 21, wherein the cell of the endothelial cell lineage is an endothelial progenitor cell (EPC).

23. The method according to claim 22, wherein the microvesicles are administered by intravenous infusion.

24. The method according to claim 23, wherein the microvesicles are administered at a dose comprised between 0.1 and 10 micrograms/Kg recipient weight.

25. A method of treating type I or type II diabetes by pancreatic islet transplantation, comprising administering microvesicles (MVs) derived from a cell of the endothelial cell lineage to the transplant recipient.

26. The method according to claim 25, wherein the cell of the endothelial cell lineage is an endothelial progenitor cell (EPC).

27. The method according to claim 26, wherein the microvesicles are administered by intravenous infusion.

28. The method according to claim 27, wherein the microvesicles are administered at a dose comprised between 0.1 and 10 micrograms/Kg recipient weight.

29. The method according to claim 25, wherein the pancreatic islet transplantation procedure includes at least one step in which the recipient is subjected to rapamycin-based immunosuppression before and/or during and/or after transplantation.